Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 9
Treatment-assignment count: 0
Stratification count: 0
Manual Review Required
HER2 / ERBB2 amplification
breast cancer · Therapy Not Normalized
HER2 / ERBB2 amplification is flagged as manual review required because public trials show inclusion required evidence in 12 contexts. FDA CDx context exists.
Threshold snippets
Fragmentation view
Threshold count: 0
Common snippets: None extracted
Threshold label: Low
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Exists
CDx maturity score: 5/5
Confidence: Low
Patent-density signal
Diagnostic appendix
Signal count: 0
Recent signals: 0
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT03944499 | https://clinicaltrials.gov/study/NCT01210768 | https://clinicaltrials.gov/study/NCT03387553 | https://clinicaltrials.gov/study/NCT03696030 | https://clinicaltrials.gov/study/NCT03878342 | https://clinicaltrials.gov/study/NCT07233928 | https://clinicaltrials.gov/study/NCT04142554 | https://clinicaltrials.gov/study/NCT01565499 | https://clinicaltrials.gov/study/NCT02365805 | https://clinicaltrials.gov/study/NCT07486089 | https://clinicaltrials.gov/study/NCT02398773 | https://clinicaltrials.gov/study/NCT00073528